BeOne Medicines achieved total Q4 revenue of $1.5 billion, a 33% increase year-over-year, driven by the global success of BRUKINSA which reached $1.1 billion in quarterly sales. The company transitioned to a GAAP net income of $66.5 million compared to a net loss in the prior year, supported by improved operating leverage and product margin expansion to 90.4%.

BeiGene posted total revenue of $1.13 billion for Q4 2024, reflecting a 78% increase year-over-year. The company narrowed its GAAP operating loss and achieved positive non-GAAP operating income. The success was primarily driven by BRUKINSA, which led the market in new CLL patient starts in the U.S. and expanded in Europe.

BeiGene reported a strong third quarter in 2024, achieving $1 billion in total revenue, driven by BRUKINSA sales. The company also reduced its GAAP loss and achieved its second consecutive quarter of positive non-GAAP operating income. They are expanding their oncology pipeline and global reach.

BeiGene reported a strong first quarter in 2024, with total revenues of $752 million, an increase of 68% compared to the same period in 2023. The company's growth was primarily driven by BRUKINSA product sales in the U.S. and Europe. BeiGene is also making significant improvements in operating leverage as it progresses towards sustainable profitability.

BeiGene's first quarter 2023 results showed strong product revenue growth of 56.9% year-over-year, driven by BRUKINSA and tislelizumab. The company is focused on operational excellence and financial discipline to bring affordable medicines to patients globally.

BeiGene reported strong fourth quarter and full year 2022 financial results, with product revenue reaching $339.0 million for the quarter and $1.3 billion for the year, representing a 72.3% and 97.9% increase, respectively, compared to the prior-year periods. The growth was primarily driven by increased sales of BRUKINSA and tislelizumab.

BeiGene reported a strong third quarter with product revenue increasing by 82% year-over-year. BRUKINSA and tislelizumab were key growth drivers. The company's total product revenue this year has exceeded $1 billion.

BeiGene reported a 120% increase in product revenue for Q2 2022, driven by BRUKINSA and tislelizumab. The company is progressing with regulatory filings and clinical trials for its key drug candidates. With a strong capital position, BeiGene is focused on expanding its commercial portfolio and advancing its R&D programs.

BeiGene reported a strong first quarter with a 146% increase in product revenue, driven by growth in BRUKINSA and tislelizumab sales. The company also made progress in clinical trials and manufacturing operations, including the groundbreaking of a U.S. manufacturing and clinical R&D facility.

BeiGene reported a strong fourth quarter and full year 2021, marked by significant revenue growth driven by product sales and collaborations. The company's strategic focus on internal development and commercialization, along with key partnerships, has positioned it for continued growth. BRUKINSA and tislelizumab sales contributed significantly to the revenue increase.

BeiGene reported a strong third quarter with a 111% increase in product revenue compared to the prior year period. The company saw significant growth in sales of BRUKINSA and tislelizumab, along with the launch of a new product from the Amgen collaboration. BeiGene also achieved important regulatory milestones, including the FDA acceptance of the BLA for tislelizumab and approvals for BRUKINSA in new indications and markets.

BeiGene reported a notable increase in product revenue, reaching $138.6 million in the second quarter of 2021, a 111% increase compared to the same period last year. The company saw growth in sales of BRUKINSA and tislelizumab, and continued advancements in its pipeline, including positive Phase 3 trial data and new regulatory approvals.

The document provides gross profit margin ratios for Celgene products, Amgen product, BRUKINSA®, and Tislelizumab for different periods. It highlights the financial information prepared in accordance with both PRC GAAP and U.S. GAAP.

BeiGene reported a product revenue increase of 76% for the fourth quarter, reaching $100.10 million, driven by sales of tislelizumab and BRUKINSA. The company also highlighted its collaboration agreement with Novartis and positive Phase 3 trial results for tislelizumab.

BeiGene reported an increase in product revenue driven by sales of tislelizumab in China and BRUKINSA in the United States and China. The company is focused on expanding its pipeline and commercial opportunities.

BeiGene reported a product revenue increase of 13% compared to the same period last year, reaching $65.64 million. The company raised net proceeds of approximately $2.07 billion through a registered direct offering.

BeiGene reported a decrease in total revenue primarily due to the lack of collaboration revenue and decreased product sales of ABRAXANE, REVLIMID and VIDAZA in China, which was partially offset by initial sales of tislelizumab in China and BRUKINSA in the United States. They launched tislelizumab in China and are managing the challenges of COVID-19 to maintain momentum in their development program.

BeiGene reported a Q4 2019 revenue of $56.89 million, primarily from product sales. The quarter saw increased R&D and SG&A expenses, leading to a net loss of $388.06 million. The company highlighted key approvals and collaborations, while also acknowledging potential COVID-19 impacts.